Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
APX3330
APX2009 and APX2014
Phentolamine Ophthalmic Solution 0.75%
Scientific Posters and Publications
Partnerships
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia
Completed
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Events
Investors
Investors
Overview
News / Events
Overview
Press Releases
Events
Email Alerts
Company Information
Overview
Presentations
Management Team
Contacts
FAQ
Financial Information
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Overview
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Contacts
RSS News Feed
News / Events
Overview
Press Releases
Events
Email Alerts
Panel Discussion on New Advances for Presbyopia
Jan 8, 2021 • 12:00pm EDT
Audio
Webcast
